Key Highlights

  • STAAR Surgical Company (NASDAQ:STAA) quoted at USD 29.80, up 9.68% in premarket trading on November 5, 2026, a day after reporting third quarter 2026 results.
  • Net sales were USD 83.4 million, down 12% from USD 94.7 million, though excluding USD 25.9 million of deferred China sales in the prior-year quarter, sales rose 21%.
  • GAAP Net Income was USD 5.6 million, or USD 0.11 per diluted share, with gross Margin at 70.9% against 82.2% a year earlier.
  • Cash, equivalents and investments reached USD 206.4 million with no debt, and a USD 50 million share repurchase program was authorized in September 2026.

Third Quarter Results Drive the Move

STAAR Surgical Company (NASDAQ:STAA) reported third quarter 2026 results on November 4, 2026, for the quarter ended October 2, 2026. Net sales were USD 83.4 million, down 12% from USD 94.7 million. The comparison is distorted: the prior-year quarter included USD 25.9 million of previously deferred China sales, and excluding that amount sales grew 21%. China contributed USD 39.3 million, down 30% reported but up 31% on the adjusted basis, while sales outside China were USD 44.1 million, up 13%. In premarket trading on November 5, 2026, per the premarket quote, the shares stood at USD 29.80.

Margins, Cash and Management Rationale

Gross margin was 70.9%, against 82.2% a year earlier, which included the deferred China revenue; the prior-year figure was 75.5% without it. Operating Income was USD 5.5 million and adjusted EBITDA was USD 14.4 million, or USD 0.28 per diluted share. For the first nine months, net sales were a record USD 270.5 million, up 48.9%, with GAAP net income of USD 18.8 million and free Cash Flow of USD 23.4 million. Chief Executive Officer Warren Foust said the results give the company confidence to raise its ambitions. Chief Financial Officer Deborah Andrews said the fourth quarter gross margin should exceed the third as temporary cost pressures ease.

Risks and What to Watch Next

The company gave qualitative rather than numeric guidance, so investors lack a hard full-year target to measure against. China seasonality is expected to moderate Revenue and Earnings in the fourth quarter, though not free cash flow. Management cited industry data showing laser vision correction procedures fell 5.8% in 2026, a reminder that refractive Demand is cyclical. The Merger agreement with Alcon was terminated on January 6, 2026, and merger-related costs of USD 6.7 million were recorded in the first nine months. Operating expenses remain on track for the USD 225 million full-year target, and two presbyopia products are expected to begin first-in-human enrollment within months, pending regulatory authorizations.

Where Things Stand

Yes, the move looks tied to results, but it is a premarket quote that can fade. STAAR Surgical Company (NASDAQ:STAA) showed sales growth of 21% on an adjusted basis, a return to GAAP profit and a cash pile of USD 206.4 million, which supports the positive reaction. Against that, the reported 12% sales decline, a lower gross margin and the absence of numeric guidance leave room for debate. The next markers are fourth quarter margin progress, China shipment trends and the first presbyopia product enrollments, none of which carry confirmed dates in the company release.